November 2023 Medical News Summary
Listen now
Description
Why Physicians Don’t Deprescribe Medicines; What to Know About Wegovy’s Rare but Serious Adverse Effects; What to Know About Zepbound, the Newest Antiobesity Drug
Related Content:
As Semaglutide’s Popularity Soars, Rare but Serious Adverse Effects Are Emerging FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management Deciding When It’s Better to Deprescribe Medicines Than to Continue Them
More Episodes
Which Variant Will Updated COVID-19 Vaccines Target This Fall? COVID-19 May Protect Against the Common Cold
Related Content:
Picking the Optimal Variant to Target in Updated COVID-19 Vaccines Is Tricky COVID-19 May Protect Against the Common Cold—Here’s Why Knowing That Could Lead to Better...
Published 07/26/24
Endocrinologist Robert Gabbay, MD, PhD, the ADA’s chief scientific and medical officer, speaks with JAMA Medical News about clinical research highlights from the annual meeting, including some of the latest data on blockbuster weight loss medications, “game-changing” diabetes technologies, and a...
Published 07/26/24
Published 07/26/24
Links
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
